Cover storyDiscover how pharma leaders can build quality sustainability through resilient systems, adaptive culture and a culture of continuous improvement.
Rezubio doses first patients in Phase I trial of RZ-520, an inhaled drug designed to sustain pulmonary exposure while limiting systemic distribution.
Neurizon names Dr. Chris Bremer CEO, bringing 20+ years of pharma and biotech leadership across drug development and commercialisation.
Elix and Axcelead DDP formalise a research agreement combining generative AI with TPD expertise to address challenging drug targets.
Inhibitor Therapeutics proposes surgically eligible BCCs as primary endpoint and seeks FDA guidance on using Tang placebo data as external control for its BCCNS itraconazole program.
Latest edition
Interview
Interview20260622153015.png&w=1920&q=75&dpl=dpl_HMJNvbv4RjMyfGws7qMCf2tLmLhC)
Interview
Podcast
Sep 28
Oct 06
Nov 18From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
20260804110923.webp&w=1920&q=75&dpl=dpl_HMJNvbv4RjMyfGws7qMCf2tLmLhC)
